FKB327与阿达木单抗参照药治疗活动性类风湿关节炎的长期安全性、免疫原性与疗效比较
本文报告FKB327(阿达木单抗生物类似药)与参照药(RP)在甲氨蝶呤控制不佳的活动性类风湿关节炎(RA)患者中的随机双盲3期研究及开放标签扩展(OLE)研究数据。双盲研究纳入728例患者,645例进入OLE,截至第76周,各治疗序列ACR20应答率相似,安全性和抗药抗体发生率相当,单次或两次转换治疗未影响疗效、安全性和免疫原性。
要点
- FKB327与阿达木单抗参照药在活动性RA患者中疗效、安全性和免疫原性相似。
- OLE第30周各治疗组ACR20应答率为83.2%至85.9%,截至第76周各序列间保持稳定。
- 单次或两次转换治疗未影响疗效、安全性和抗药抗体发生率。
核心结论
- FKB327与参照药治疗RA患者长达2年,疗效、安全性和免疫原性相似,且不受单次或两次转换治疗影响。
研究设计与样本
- 随机双盲3期研究:活动性RA且甲氨蝶呤控制不佳患者按1:1随机接受FKB327或参照药40mg皮下注射每两周一次,治疗24周。
- 开放标签扩展研究:完成双盲研究的患者按2:1重新随机接受FKB327或参照药,三分之二继续原治疗,三分之一转换治疗30周,所有患者至第76周均接受FKB327。
主要发现
- 双盲研究728例患者中645例进入FKB327-OLE研究。
- OLE第30周所有治疗组ACR20应答率为83.2%至85.9%。
- 截至第76周,无论单次或两次转换治疗,所有患者ACR20应答率保持稳定,各治疗序列相似。
- 各治疗序列的安全性和抗药抗体发生率相当。
关键数值与推荐
- ACR20应答率:OLE第30周所有治疗组为83.2%至85.9%。
临床怎么用
- FKB327可作为阿达木单抗参照药的生物类似药用于活动性RA患者,转换治疗未显示疗效、安全性或免疫原性方面的担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVE: FKB327 is a biosimilar of the antitumour necrosis factor adalimumab reference product (RP). A randomised, double-blind (DB) phase 3 study compared the efficacy of FKB327 with the RP in patients with active rheumatoid arthritis (RA) inadequately controlled with methotrexate (MTX). A subsequent randomised open-label extension (OLE) study with treatment switching assessed long-term safety, efficacy, pharmacokinetics and immunogenicity of FKB327 compared with the RP. METHODS: Patients with moderate-to-severe, active RA on a stable dose of MTX were randomised 1:1 to receive FKB327 or the RP (40 mg subcutaneously every other week) for 24 weeks. Patients who completed the DB study were enrolled in the OLE and rerandomised 2:1 to receive FKB327 or the RP; two-thirds continued on the same treatment and one-third switched for 30 weeks. All patients received FKB327 through Week 76. Long-term efficacy, safety and immunogenicity were assessed. RESULTS: Of 728 patients in the DB study, 645 were enrolled in the FKB327-OLE study. The American College of Rheumatology (ACR)20 response rates for all treatment groups at Week 30 in the OLE ranged from 83.2% to 85.9%. ACR20 response rates remained stable for all patients regardless of single- or double-switching treatment and were similar for all treatment sequences through Week 76. The safety profile and incidence of antidrug antibodies were comparable across sequences. CONCLUSION: Efficacy, safety and immunogenicity were similar among patients with RA treated with FKB327 or the RP for up to 2 years, and were not affected by single- or double-switching treatment.
引用
- Genovese MC, Kellner H, Arai Y, et al. Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies. RMD Open. 2020. PMID: 32371430. doi:10.1136/rmdopen-2019-000987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。